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Abstract
Histone deacetylases (HDACs) play a crucial role in the proper 
regulation of cellular functions through their connection with 
chromatin and transcriptional regulation. Alterations in HDAC 
activity have been reported  in several types of cancer encouraging 
development of HDAC inhibitors (HDACis) for cancer treatment. The 
antitumor activity of HDACi has been demonstrated, in clinical trials, 
in both solid and non solid neoplasias  at doses well tolerated by 
patients. However, the molecular basis for their tumor selectivity is 
unknown. Anaplastic thyroid carcinoma (ATC) is one of the most 
aggressive malignancies, having a poor prognosis and being 
refractory to conventional chemo- and radiotherapy. To the aim to 
find an innovative therapy for the treatment of ATCs, we studied the 
effects of two potent HDACis, SAHA and MS-275, on rat thyroid cell
lines transformed by the v-ras-Ki oncogene which is frequently 
mutated in ATCs. We show that: i) HDAC 1 and HDAC 2 are 
overexpressed in anaplastic thyroid carcinomas compared to normal 
thyroid; ii) SAHA and MS-275 induce apoptosis selectively in 
completely transformed rat thyroid cells; iii) TNF-related apoptosis-
inducing ligand (TRAIL) is the main mediator of cell death induced 
by SAHA; iv) SAHA stabilize TRAIL protein by affecting its 
proteasome-mediated degradation. 
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1 INTRODUCTION
1.1 Thyroid gland
The thyroid gland, which is one of the largest endocrine organ in 
humans, regulates systemic metabolism through thyroid hormones.
It is composed of spherical follicles that selectively absorb iodine 
from the blood for that production of thyroid hormones (T3 and T4). 
The follicles are surrounded by a single layer of thyroid epithelial 
cells named follicular cells, which synthesize and secrete T3 (L-
triiodothyronine) and T4 (L-thyroxine) hormones under the control of 
the hypothalamic–pituitary axis with negative feedback by the 
thyroid hormones (Kondo T, 2006) (Figure 1). Thyrotropin-releasing 
hormone (TRH), which is secreted from the hypothalamus, 
stimulates the release of thyroid-stimulating hormone (TSH) from the 
anterior pituitary gland. TSH stimulates the follicular cells to 
synthesize and secrete thyroid hormones.. Parafollicular cells (or C 
cells) are in the interstitial spaces outside the thyroid follicles and 
produce the calcium-regulating hormone calcitonin.
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Figure 1. Schematic representation of thyroid gland structure and function.
Thyroid follicular cells synthesize, store and secrete thyroid hormones T3 and 
T4 under the control of the hypothalamic-pituitary axis with negative feedback 
by the thyroid hormones.
1.2 Thyroid cancer
Tumors are the result of the accumulation of different modifications 
in critical genes involved in the control of cell proliferation. In a large 
number of carcinomas with worst prognosis, lesions are not 
diagnosed until the disease is at an advanced stage. Although 
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various therapeutic approaches are followed in clinical practice, 
most of them are not life-saving. 
Thyroid nodules can be hyperplastic benign adenomas or malignant 
lesions, and can be derive from thyroid follicular epithelial cells or C 
cells.  However, more than 95% of thyroid carcinomas are derived 
from follicular cells (Kondo T, 2006) and are the most common 
endocrine malignancies, with an estimated 25,000 new cases 
diagnosed annually in the United States. Conversely, only 3% of 
thyroid tumors, referred to as medullary thyroid carcinoma, are of C-
cell origin.
Thyroid neoplasms represent a good model for studying the events 
involved in epithelial cell multistep carcinogenesis, because they 
comprise a broad spectrum of lesions with different degrees of 
malignancy which are diagnosed on the basis of histological and 
clinical parameters. Follicular cell-derived thyroid tumors include: 1) 
benign adenomas, which are not invasive and very well 
differentiated; 2) carcinomas, which are divided into well-
differentiated, poorly differentiated and undifferentiated types. Well-
differentiated thyroid carcinomas are papillary (PTC) and follicular 
(FTC) types, being differentiated and having a good prognosis 
(Kondo T, 2006; Saltman B, 2006). Most well-differentiated thyroid 
carcinomas are 2–4 times more frequent in females than in males 
and manifest in patients who are between years of age. The papillary 
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carcinoma is defined as a malignant epithelial tumor, showing 
papillar and follicular architecture and typical nuclear alterations 
(Hedinger C,1989). Particularly, “occult” papillary carcinomas are 
slow-growing and clinically silent carcinomas. PTCs represent more 
than 70% of thyroid malignant tumors and occurr two to three-fold 
more frequently in females (Salabe GB, 1994). Exposure to ionizing 
radiation and radioactive contamination of the environment increase 
the risk of developing this kind of cancer as evidenced by the effects
of the atomic bombs of Hiroshima and Nagasaki (1945), nuclear 
testing in the Marshall Islands (1954) and Nevada (1951–1962), and 
the more recent nuclear accident in Chernobyl (1986) (Nikiforov Y, 
1994; Kazakov VS,1992). After the Chernobyl disaster, the effects of 
radiation exposure were most pronounced in children. External 
beam-radiation exposure in childhood for the treatment of benign 
conditions of the head and neck also increased the risk of papillary 
carcinoma (Ron E, 1995).
Differently from papillary carcinomas, which can invade local lymph 
nodes, follicular carcinomas are characterized by haematogenous 
spread and distant metastasis. FTCs represent 10% of thyroid 
carcinomas, they are more common in females than in males and 
rarely associated with radiation exposure.
Poorly differentiated (PDTC) and undifferentiated anaplastic 
carcinomas (ATC) seem to derive from the progression of 
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differentiated carcinomas (Van der Laan BF, 1993 ). Although the 
ATC represents  2-5% of thyroid malignant tumors, it is one of the 
most lethal human neoplasms being rapidly–growing, very 
aggressive and always fatal. Anaplastic cancers invade adjacent 
structures and metastasize extensively to cervical lymph nodes and 
distant organs such as lungs and bones. Finally, PDTCs, 
representing 7% of thyroid carcinomas, are morphologically and 
behaviourally intermediate between well-differentiated and 
undifferentiated thyroid carcinomas. Medullary carcinomas of the 
thyroid are significantly less common than follicular cell-derived 
thyroid tumor and include multiple endocrine neoplasia 2A and 2B 
(MEN2A, MEN2B) and familial medullary thyroid carcinoma. This 
type of thyroid tumor is characterized by gain-of-function mutations of 
RET proto-oncogene.
1.3 Genetic lesions in thyroid carcinomas
The involvement of several oncogenes has been demonstrated in 
thyroid carcinomas (Figure 2). Mutations or rearrangements in 
genes encoding RET, NTRK1, BRAF or Ras are detectable in nearly 
70% of all cases in well-differentiated thyroid carcinoma (Table 1)
(Kondo T, 2006). RET is a transmembrane receptor-tyrosine kinase
endcoded by RET proto-oncogene which is rearranged in sporadic 
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and radiation-associated papillary carcinoma. The most common
RET chimeric genes are H4(CCDC6)–RET (also known as 
RET/PTC1) and ELE1–RET (also known as RET/PTC3) in papillary 
carcinoma (Kondo T, 2006). The neurotrophic receptor-tyrosine 
kinase NTRK1 (also known as TRK and TRKA) is another proto-
oncogene encoding a transmembrane tyrosine-kinase receptor for 
nerve growth rearranged in 5-13% of sporadic but only 3% of 
radiation-induced papillary thyroid tumors. TPM3, TPR and TFG are 
the main fusion partners in the chimeric oncogenes TRK, TRK-T1 
and TRK-T2, and TRK-T3 (Kondo T, 2006). BRAF is a 
serine/threonine kinase involved in cell proliferation pathways.
BRAFV600E is the most common alteration in sporadic papillary 
carcinoma. BRAF mutations are found in 29–69% of papillary thyroid 
carcinoma, in up to 13% of poorly differentiated thyroid carcinoma 
and 35% of undifferentiated anaplastic thyroid carcinoma but not in 
follicular thyroid carcinoma (Kondo T, 2006).
Genetic alteration PTC FTC PDTC ATC
RET rearrangement 13-43% 0% 0-13% 0%
Braf mutation 26-69% 0% 0-13% 10-35%
NTRK1 rearrangement 5-13% Unknown Unknown Unknown
Ras mutation 0-21% 40-53% 18-27% 20-60%
TP53 mutation 0-5% 0-9% 17-38% 67-88%
           
Table1. Genetic defects in papillary (PTC), follicular (FTC), poorly differentiated 
(PDTC) and anaplastic (ATC) thyroid carcinomas.
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Ras mutated is one of the most common genetic lesions found in 
human tumors. Ras proto-oncogenes known as HRAS, KRAS and 
NRAS play a crucial role in thyroid tumorigenesis. A low incidence of 
Ras mutation was found in well-differentiated thyroid carcinoma 
whereas this phenomenon is more frequent in poorly differentiated 
and undifferentiated thyroid carcinoma, thus indicating its
importance in thyroid tumor progression.    
The critical role of ras gene activation in some thyroid cancer 
histotypes was confirmed by the induction of thyroid follicular 
carcinomas associated to lung metastasis following the injection of 
the Kirsten murine sarcoma virus into the thyroid gland of adult 
Fischer rats (Portella G, 1989). The important role of ras oncogene 
in thyroid cancer was also demonstrated in human follicular and 
anaplastic carcinoma where the frequency of mutation in this gene is 
about 50% (Nikiforova MN, 2003). Finally, PAX8-PPAR-
rearrangements which juxtaposes the thyroid transcription factor 
PAX8 to the peroxisome proliferator-activa ed receptor (PPAR-) 
and impairment of the TP53 tumor suppressor gene were also
reported in follicular and anaplastic carcinomas, respectively 
(Suarez HG, 1990; Fagin JA,1993)
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Figure 2. Schematic representation of genetic alterations involved in neoplastic 
transformation in different histotypes of thyroid carcinomas.
1.4 Therapy
Surgical resection and radioactive iodine can be an effective 
treatment for well-differentiated tumors. In fact, most thyroid cancer 
cells retain the ability to absorb and concentrate iodine. This 
provides a perfect "chemotherapy" strategy. Radioactive Iodine is 
given to the patient with thyroid cancer after their cancer has been 
removed. Remaining  cancerous thyroid cells will absorb iodine and 
will be destroyed by the radioactivity (Kondo T, 2006). However, 
undifferentiated anaplastic thyroid carcinomas have a poor 
prognosis being refractory to conventional chemotherapy and 
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radiotherapy (Kondo T, 2006). Most of these cancers are so 
aggressively attached to vital neck structures that they are 
inoperable and death usually occurs within 1 year of diagnosis. A 
novel approach that is currently being tested for the treatment of 
thyroid cancer is the use of epigenetic drugs like Histone 
Deacetylases Inhibitors (HDACis).
1.5 Epigenetic control of gene expression
In eukaryotes DNA is packaged into chromatin fibers to achieve 
compaction, enabling the entire genome to fit into the nucleus, and
allowing DNA transcription, replication, and repair, when necessary
(Figure 3). 
Figure 3. Organization of DNA into chromatin, Nucleosome fibers are packaged 
into higher order structures giving rise to chromosomes.
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The nucleosome is the basic repeating unit of chromatin polymer
and consists of 146 bp of DNA wrapped around a histone octamer
(Marks PA, 2001). Histones are small basic proteins conserved 
throughout evolution and consist of a globular domain flanked by a 
carboxy-terminal and a lysine rich amino-terminal tail composed of
positively charged residues. The core histone octamer  is formed by 
two copies of each of histones H2A, H2B, H3 and H4 organized in 
an H3-H4 tetramer and two H2A-H2B dimers. The binding of histone 
H1 to linker DNA sequences between nucleosomes leads to a 
further chromatin compaction, by mechanisms that remain poorly 
defined. 
Figure 4. Schematic representation of a nucleosome. DNA is wrapped around 
core histone octamer which contains two H3-H4 tetramers centrally located and 
two flanking H2A-H2B dimers. Histone H1 links nucleosomes into higher order 
structures.
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Histone lysine tails protruding from the nucleosome are sites of  
post-translational modifications including acetylation, methylation 
and ubiquitination of lysine (K) residues, phosphorylation of serine 
(S) and threonine (T) residues, methylation of arginine (R) and ADP-
ribosylation of glutamic acid residues (Fischle W, 2003; Zhang Y,
2001) (Figure 5).
Figure 5. Covalent modifications of the N-terminal tail of the core histones. 
Acetylations are shown as red hexagons; methylation as yellow and orange 
squares; phosphorylations as green circles.
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Strahl and Allis (Strahl BD, 2000) proposed that distinct histone 
modifications, on one or more tails, act sequentially or in 
combination to form a 'histone code' that is, read by other proteins 
leading to distinct downstream events. This theory states that post-
translational modifications can act through two mechanisms that are 
not mutually exclusive: (i) by structurally changing the chromatin 
fiber through internucleosomal contacts thus regulating the access 
of transcription factors to the DNA; and (ii) by generating docking 
sites for effector molecules that, in turn, initiate distinct biological 
processes. The histone code is part of the epigenetic information 
found into the cells. The term “epigenetics” refers to mitotically and 
meiotically heritable changes in gene expression that are not coded 
in the DNA sequence itself (Egger G, 2004). Indeed, DNA 
methylation is another well studied epigenetic mechanism.
Methylation at the C-5 position of cytosine residues present in CpG 
dinucleotides by DNA methyltransferases (DNMTs) is generally 
considered to facilitate static long-term gene silencing (Lund AH, 
2004).
1.6 Histone acetylation
To date, acetylation is the most extensively studied histone post-
translational modification and involves the transferring of an acetyl
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group from the metabolic intermediary acetyl coenzyme A to the ε-
amino group of a lysine residue. The primary effect produced by 
acetylation is the partial neutralization of the positive charge of the 
histones, thus decreasing their affinity for the DNA, altering 
nucleosome-nucleosome interactions and enabling chromatin 
decondensation to allow transcriptional activation (Jenuwein T, 
2001; Vaquero A, 2003). Although it is known that the four core 
histones (H2A, H2B, H3, and H4) can be acetylated in their N-
terminal tails, the H3 and H4 modifications are mainly responsible
for the effect on transcription.
The balance between acetylated and deacetylated states of 
chromatin is regulated by histone acetyltransferase (HAT) and 
histone deacetylase (HDAC) enzymes (Marks PA, 2001; Minucci S, 
2006). HATs transfer acetyl groups to amino-terminal lysine 
residues in histones, which results in local expansion of chromatin 
and increased accessibility of transcription factors to DNA, whereas 
HDACs catalyse the removal of acetyl groups, leading to chromatin
condensation and transcriptional repression (Figure 6).
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Figure 6. Schematic representation of the equilibrium between HDAC and HAT 
activities.
1.7 HDAC classification
Mammalian HDACs are divided into four classes on the basis of 
their sequence homology to yeast HDACs: a) class I includes HDAC 
1, 2, 3 and 8 which are homologous to yeast HDAC Rpd3; b) class II 
is further subdivided into two subclasses, IIa (HDAC 4, 5, 7, 9) and 
IIb (HDAC 6 and 10), based on their sequence homology and 
domain organization; class II HDACs are homologous to yeast 
Hda1; c) class III HDACs  are the sirtuins (SIRT1-7) which are 
homologous to yeast Sir2 family of proteins; d) HDAC11 is 
phylogenetically different from both class I and class II enzymes and 
is considered as a separate class named class IV (Gallinari P, 2007)
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(Figure 7). HDACs belonging to classes I, II and IV require a zinc ion 
in the catalytic domain to mediate deacetylation catalysis. 
Conversely, sirtuins are dependent on NAD+ as a cofactor (Altucci L,
2009; Minucci S, 2006). Class I HDACs are generally localized to 
the nucleus, and are ubiquitously expressed in many human tissues 
(Gallinari P, 2007; Vaquero A, 2003). Class I HDACs have also 
been shown to interact with factors involved in other functions, such 
as DNA or histone methyltransferases (Dnmts and Polycomb group 
proteins) (Vaquero A, 2003). Class IIa HDACs (subtypes 4,5,7 and 
9) contain a highly conserved C-terminal deacetylase catalytic 
domain while Class IIb HDACs (subtypes 6 and 10) are 
characterized by an additional deacetylase domain, although this
duplication is partial in the case of HDAC 10. Class II HDACs can 
shuttle between the nucleus and cytoplasm, suggesting potential 
extranuclear functions by regulating the acetylation status of 
nonhistone substrates (McKinsey TA, 2000). In fact, the second 
deacetylase domain of HDAC6 has been reported to deacetylate -
tubulin and Hsp90 (Gallinari P, 2007). Class II members participate 
in skeletal muscle differentiation by interaction with members of the 
muscle-specific MEF2 transcription factor family (McKinsey TA,
2000; De Ruijter AJ, 2003). HDACs are regulated by gene 
expression, subcellular localization, and post-translational 
modifications such as phosphorylation, sumoylation, proteolysis, and 
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availability of metabolic cofactors (Dokmanovic M, 2005). HDACs, 
like HATs,, do not bind to DNA directly, but are recruited to multi-
protein complexes associated with DNA which differ in their subunit 
composition. Transcription factors recruit coactivators with HAT 
activity (e.g. p300/CBP) to regulatory DNA sites, while 
transcriptional repressors recruit corepressors with HDAC activity
(Dokmanovic M, 2005). Class I and class II HDACs are often found 
as components of larger transcription factor protein complexes: 
HDAC1 and 2 are frequently found in complex with the histone 
binding proteins RbAp46/48 (retinoblastoma-associated proteins) 
and SAP30 (Sin3-associated protein), Sin3 (general transcriptional 
co-repressor) or MBD3 (methyl-CpG binding domain protein 3), 
MTA2 (metastasis associated 1), Mi2 (dermatomyositis-specific 
autoantigen) forming the Sin3 and NuRD (nucleosome remodeling 
and deacetylase) corepressor complexes, respectively. The 
components of Sin3 complex impart specificity for its localization to 
certain regions of the genome and regulate its activity. NuRD 
complex represses transcription more globally but also interacts with 
gene-specific transcription factors. The RbAp proteins, present in 
both complexes, have a role in stabilizing the interaction of each 
complex with the core histones of the nucleosomes. HDAC3 is found 
in complex with the nuclear hormone corepressors NCoR (nuclear
receptor corepressor) and SMRT (silencing mediator for retinoid and 
                                                                           
20
thyroid hormone receptors). In fact, HDAC3 is especially involved in 
the repression of genes connected with nuclear receptor signaling.
HDAC-containing complexes can interact with a wide variety of 
transcriptional regulatory proteins, most of them DNA binding 
proteins, such as the repressors and transcription factors. Class II 
HDACs also interact with the NCoR, SMRT, and the Bcl6 gene-
specific co-repressor BCoR.
Figure 7. HDAC classification. Structure and localization of Class I and II HDAC 
enzymes.
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1.8 Epigenetics and cancer
Cancer is usually characterized by genetic defects such as gene 
mutations and chromosomal abnormalities, which cause loss of 
function of tumor-suppressor genes and/or gain of function or 
hyperactivation of oncogenes. However, there is growing evidence 
that epigenetic control of gene expression is also crucial to the onset 
and progression of cancer. Notably, in contrast to genetic 
modifications, epigenetic alterations are transient and can be 
reversed, at least partially, by treatment with epigenetic drugs
(Bolden JE, 2006). Disruption of HAT or HDAC activity can be 
associated with the development of cancer (Marks PA, 2001).
Translocations, amplifications, deletions and point mutations  have 
been reported for HAT genes (p300, PCAF and CBP) in various 
human cancers, whereas mutations in HDAC genes are rare in 
human tumors. In fact, abnormal HDAC activity, due to its
overexpression or aberrant recruitment by altered protein partners, 
is  more common in different types of cancer (Marks PA, 2001; 
Dokmanovic M, 2005; Minucci S, 2006; Bolden JE, 2006). Increased 
expression of HDAC1 has been detected in gastric cancers, 
oesophageal squamous cell carcinoma, and hormone refractory 
prostate cancer, while HDAC2 overexpression has been detected in 
colon cancer (Dokmanovic M, 2005).
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Acute promyelocytic leukaemia (APL) was the first model disease in 
which the involvement of HDACs was demonstrated (Minucci S, 
2006). This form of leukaemia is characterized by an arrest of the 
leukaemic cells at the promyelocytic stage of myeloid differentiation
related to the presence of the fusion protein of retinoic acid receptor-
 (RAR) with one of the following proteins: promyelocytic leukaemia 
(PML) in > 95% of cases, promyelocytic leukaemia zinc finger 
(PLZF) in 5% of cases or other genes sporadically. RAR functions 
as a transcription factor. In the absence of  retinoic acid (RA), RAR 
is found at DNA response elements of RA-regulated genes and is 
associated with HDAC containing complexes; this contributes to the 
transcriptional silencing of these genes. At physiological
concentrations of RA, a conformational switch leads to the release 
of the HDAC-containing complexes and to the association of RAR 
with transcriptional co-activators (including HATs) and subsequent 
transcriptional activation (Minucci S, 2006). PML-RAR and PLZF-
RAR recruit HDACs through NCoR and SMRT and cause aberrant 
transcriptional repression that prevents differentiation (De Ruijter AJ, 
2003). Pharmacological doses of retinoic acid induce clinical 
remission in APL patients expressing PML-RAR. This effect is due 
to removal of HDAC-dependent repression from RAR target genes 
and the resulting re-differentiation of the leukaemic cells (Minucci S, 
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2006). Conversely, patients expressing PLZF–RAR, which is 
insensitive to pharmacological doses of RA, require a combined 
treatment retinoic acid plus HDAC inhibitor to allow HDAC release 
and reactivation of RAR-dependent gene transcription. The 
transcriptional repressor LAZ3/BCL6 (lymphoma-associated zinc 
finger-3/B cell lymphoma 6) is overexpressed in non-Hodgkin’s 
lymphoma, and causes aberrant transcriptional repression through 
recruitment of HDACs leading to oncogenic transformation (Marks 
PA, 2001). AML1-ETO is another fusion protein which abnormally 
recruits HDAC-containing complexes (Marks PA, 2001; Altucci L, 
2005). The fusion of the DNA binding domain of the transcription
factor AML1 to the entire coding sequence of another transcription 
factor named ETO, is produced by a translocation common in acute 
myeloid leukaemia (Altucci L, 2005). However, these fusion proteins 
promote DNA methyltransferases and histone methyltransferases
recruitment leading to compaction of chromatin. Furthermore, 
deregulation of transcription factors or chromatin modifiers targeting 
HDACs to specific genomic regions have been observed in solid 
tumors affecting the balance of histone acetylation. Alteration in 
histone acetylation status  can lead to changes in chromatin 
structure and transcriptional dysregulation of genes that are involved 
in the control of cell-cycle progression, differentiation and/or 
apoptosis. DNA and histone methylation, tightly linked to chromatin 
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repressive states, also have an important role in tumorigenesis and 
are dependent on the concomitant action of HDACs (Egger G, 2004; 
Feinberg AP, 2004; Minucci S, 2006). In these examples, 
transcriptional repression is mainly mediated by the recruitment of 
HDACs and provides a mechanistic rationale for the treatment of 
different types of tumors with inhibitors of HDAC activity.
1.9 Histone deacetylase inhibitors 
HDAC inhibitors are divided into at least five distinct classes on the 
basis of their chemical structure and pharmacological properties 
such as potency, efficacy, stability and toxicity. The classes are as 
follows: short-chain fatty acids, hydroxamic acids, electrophilic 
ketones, cyclic tetrapeptides and benzamides (Figure 8).
Figure 8. Representative structures of the main members of HDACi classes.
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Short chain fatty acids include valproic acid and butyrate which are
already used in treating epilepsy, but also inhibit class I HDACs
(Glickman MH, 2002). Particularly, valproic acid inhibits HDAC 1 and 
2 by decreasing catalytic activity and proteasomal degradation, 
respectively (Krämer OH, 2003; Yoo CB, 2006). Phase I and phase 
II clinical trials are ongoing for leukaemias and myelodysplasia to 
evaluate this drug as an antitumor agent (Dokmanovic M, 2005; 
Minucci S, 2006). Butyrate was the first HDAC inhibitor to be 
identified and the related compound phenylbutyrate has been 
employed in experimental cancer therapy (Marks PA, 2001).
However, valproic acid and butyrate are less potent than other 
HDAC inhibitors and have a short plasma half-life thus requiring high 
concentration to inhibit HDACs: micromolar and millmolar 
concentrations in vitro and in vivo, respectively (Marks PA, 2001; 
Johnstone RW, 2002; Hellebrekers DM, 2007). In fact, these 
compounds are unstable and possess an acyl group which cannot 
make significant contact with the catalytic pocket due to their very  
short side chain. The structural requirements for a perfect interaction 
beteen HDACis and target enzyme are shown in Figure9.
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Figure 9. HDACi essential features responsible for optimal interactions with  
HDAC  target
Hydroxamic acids are potent HDACis and consists of a functional 
group interacting with the HDAC zinc atom, a 5-6 carbon aliphatic 
chain which mimics a lysine side chain, and a hydrophobic cap 
moiety which interacts with the edge of the catalytic pocket and 
could play a role in HDAC selectivity (Johnstone RW, 2003). This 
class includes trichostatin A (TSA), suberoylanilide hydroxamic acid 
(SAHA), pyroxamide, m-carboxycinnamic acid bishydroxamide 
(CBHA), oxamflatin, scriptaid. All hydroxamates have the property to 
inhibit class I and II HDACs at nanomolar concentration in vitro, but
TSA and SAHA are the most potent and effective inhibitors of this 
class (Kim DH, 2003; Dokmanovic M, Marks PA, 2005; Marks PA, 
2007; Pan L.N., 2007). Moreover, crystallographic analysis showed 
that both TSA and SAHA interact directly with the catalytic site of 
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HDAC inhibiting its enzymatic activity (Finnin MS, 1999) (Figure 10).
TSA is a fermentation product of Streptomyces hygroscopicus used 
as an anti-fungal agent but it was also the first natural product 
hydroxyamate discovered to inhibit HDACs (Yoshida M,1995).
SAHA has a chemical structure similar to TSA, but was generated 
from chemical synthesis and shows a weaker inhibitory activity for 
HDAC than TSA. However, SAHA is effective for the inhibition of 
tumor growth, both in vitro and in vivo, at the micromolar 
concentration, with minimal side effects and has a longer half-life 
with respect to TSA (Glick RD, 1999; Butler LM, 2000; Kim DH, 
2003; Piekarz R, 2004). Among the hydroxamic acids, SAHA has 
been shown to be the most effective HDACi, capable of inducing
early changes in gene expression profile, which include suppression 
of genes mediating proliferation and survival.
Figure 10. Schematic representation of HDAC catalytic site. (A) Interaction of 
an acetyl-lysine residue and a water molecule with the zinc cation. (B) TSA 
chelating Zn2+ in the catalytic pocket. Thick black lines represent hydrophobic 
surfaces. Thick gray lines indicate areas rich in charged  aminoacids (aspartic 
acid and histidine).
                                                                           
28
Electrophilic ketones, like trifluoromethyl and heterocyclic ketones , 
are modest HDACis with short half-life and weak antiproliferative 
activity against tumor cell lines (Gallnari P, 2007).
Cyclic tetrapeptides include depsipeptide (FK-228), apicidin, 
trapoxin and depudesin which preferentially inhibit class I HDACs
(Bolden JE,2006). Depsipeptide is a bacterial metabolite produced
as a prodrug which undergoes metabolic activation in the cell 
through the reduction of the intramolecular disulfide bond by 
reducing agents (e.g. glutathione). This reduction yields two 
dulfhydryl groups, one of which is accessible to the catalytic Zn2+ of 
HDACs (Kim DH, 2003; Dokmanovic M, 2005; Gallinari P, 2006;
Glaser KB, 2007; Pan LN, 2007). Depsipeptide possesses stronger
inhibitor activity against HDAC 1 and 2 than against class II HDAC4 
and HDAC6 at nanomolar concentrations (Furumai R, 2002; Bolden 
JE, 2006). Apicidin is a fungal metabolite able to inhibit HDACs at 
nanomolar concentrations (Dokmanovic M, 2005). Trapoxin and 
depudesin are the only HDACis which inhibit the enzyme irreversibly 
via covalent binding to the catalytic site (Marks PA, 2001). The final 
class comprises benzamide compounds such as CI-994 and MS-27-
275 (MS-275) which inhibit HDAC at micromolar concentration. CI-
994 (N-acetyl dinaline) is a relatively weak HDAC inhibitor. MS-275 
is a selective inhibitor for HDAC 1, 2 less active against HDAC3 (Hu 
E, 2003; Nebbioso A, 2005; Bolden JE, 2006; Glaser KB, 2007; Pan 
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LN, 2007).
1.10 HDACi effects: from in vitro models to clinical 
experimentation
HDACis induce growth arrest, differentiation and cell-death of 
different hematologic and solid tumor cells in culture (Drummond 
DC, 2005; Kelly WK, 2005). Many HDACis including TSA, SAHA, 
MS-275 and FK-228 administered intravenously or intraperitoneally
inhibit tumor growth in nude mice transplanted with human solid and 
nonsolid tumors  (xenograft models) such as human breast, 
prostate, lung and stomach cancers, neuroblastoma, 
medulloblastoma, multiple myeloma and leukemias with little toxicity
(Butler LM, 2000; Marks PA, 2001; De Ruijter AJ, 2003; Marks PA, 
2004; Piekarz R, 2004; Drummond DC, 2005). The marker mainly 
used to monitor dosing and HDAC biological activity in both animal 
models and cancer patients is the accumulation of acetylated 
histones in tumor and normal tissues (spleen, liver and peripheral 
mononuclear cells) (Marks PA, 2001).
Positives results obtained with HDACis in preclinical studies 
encouraged the introduction of these drugs in clinical trials.
Phenylbutyrate, like other members of the short-chain fatty acid 
class, has a short half-life and inhibits HDACs at high concentration, 
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thus requiring prolonged intravenous or oral administrations to 
achieve constant serum concentrations. However, the continuous 
infusion of the drug has increased the risk of toxic side-effects 
inducing confusion, somnolence, nausea, vomiting, dyspepsia and
fatigue in treated patients (Marks PA, 2001; Dokmanovic M, 2005).
Moreover, phenylbutyrate has shown only a modest anti-cancer 
activity in Phase I clinical studies already concluded in leukemias 
and solid tumors (Dokmanovic M, 2005; Gallinari P, 2007).
SAHA (Zolinza, Vorinostat) is the most clinically advanced HDACi 
(Hellebrekers DM, 2007; Gallinari P, 2007) approved in 2006 by the 
Food and Drug Administration (FDA) for the treatment of cutaneous 
manifestations of advanced, refractory cutaneous T-cell lymphoma
(Gallinari P, 2007). SAHA induces differentiation, cell growth arrest 
and apoptosis in many cell lines at low micromolar concentration 
and in vivo inhibits tumor growth with undetectable toxic effects in a 
wide range of animal models bearing solid tumors (including breast, 
prostate, lung and gastric cancers) and hematological malignancies
(Gallinari P, 2007). Particularly, SAHA also inhibits the progression
of spontaneous tumors that are induced with carcinogens 
(Johnstone RW, 2002; Marks PA, 2007). To date, many clinical 
studies with SAHA against different types of tumors have been 
initiated (Kelly WK, 2003). Intravenous administration of SAHA to 
patients with hematologic and solid tumors demonstrated that the
                                                                           
31
drug is well tolerated at the doses required to hyperacetylate 
histones, and promote symptomatic improvements and tumor 
regression. The dose limiting toxic effects in hematologic tumors 
were thrombocytopenia and neutropenia (Johnstone RW, 2002;
Minucci S, 2006; Marks PA, 2007). However, inhibition of 
intracellular HDAC activity needs continuous systemic drug 
exposure to achieve maximal clinical response. This requirement 
encouraged development of an oral formulation of SAHA. Phase I 
study with orally administered Vorinostat in patients with solid and 
nonsolid neoplasias demonstrated that, in this formulation, SAHA 
could be administered safely for prolonged periods of time,
maintaining the biologic effect of the drug and exhibiting a broad 
range of antitumor activity (Kelly WK, O'Connor OA, 2005). Toxic 
effects observed such as fatigue, diarrhea, anorexia and 
dehydration were reversible on cessation of therapy. Some studies
have also demonstrated additive or synergistic effect of SAHA with 
anticancer agents including chemotherapics (e.g. anthracyclins), 
DNA demethylating agents (e.g. 5-aza-2’-deoxycytidine), nuclear 
receptor ligands (e.g. retinoic acid) and  apoptotic molecules (e.g.
TRAIL ligand) (Marks PA, 2007). Phase I and phase II clinical trials 
testing SAHA as monotherapy or in combination with different 
anticancer agents are ongoing for hematologic and solid tumors 
(Piekarz R, 2004). Phase III studies for SAHA in patients with 
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malignant pleural mesothelioma and diffuse large B-cell lymphoma 
are in progress (Hellebrekers DM, 2007). As far as drug-resistance 
is concerned SAHA is able to reverse the multidrug-resistant 
phenotype downnregulating P-glycoprotein (Ruefli AA, 2002; Castro-
Galache MD, 2003; Peart MJ, 2003).
Depsipeptide (FK-228) is effective in leukaemia and lymphoma 
animal models, and recently Phase I trials have shown encouraging 
results for patients with T-cell lymphoma (Hellebrekers DM, 2007). 
Furthermore, phase II trials are ongoing to study the efficacy and 
toxicity of FK-228 (Johnstone RW, 2002; Glaser KB, 2007). 
However, in Phase II studies against solid tumors, FK-228 
demonstrated only a marginal activity and many toxic effects such 
as fatigue, nausea, vomiting, myelosuppression and a significant 
incidence of cardiac dysrhytmias (Piekarz R, 2004; Minucci S, 2006; 
Glaser KB, 2007). Nowadays, there are several other ongoing 
Phase II clinical trials testing depsipeptide in patients with renal cell 
carcinoma, acute myeloid leukaemia, multiple myeloma (Piekarz R, 
2004). Although depsipeptide is a substrate for the drug-efflux 
protein P-glycoprotein, most HDAC inhibitors can overcome 
multidrug resistance that is mediated by overexpression of P-
glycoprotein (Xiao JJ, 2005).
MS-275 inhibits the proliferation of multiple carcinoma cell lines
(human leukemia, colorectal, lung, pancreas, ovary and gastric 
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carcinomas) at micromolar concentration as well as the growth of 
tumors in mice xenograft models transplanted with the cell lines 
already tested in vitro, in a dose dependent-manner (Saito A, 1999).
A phase I study of MS-275 has been performed in patients with 
advanced solid tumors or lymphoma and this drug is now
undergoing Phase II trials (Ryan QC, 2005; Hellebrekers DM, 2007).
MS-275 has a half-life in humans longer than that predicted in 
preclinical models and the dose-limiting toxicities observed in clinical 
studies are nausea, vomiting, anorexia and fatigue (Minucci S, 2006; 
Glaser KB, 2007). This drug has potential activity in patients with
hematologic malignancies, is currently in clinical trial for melanoma 
and undergoing Phase II studies in combination with 5-azacitidine in 
non-small cell lung cancer (Saito A, 1999;  Suzuki T,1999; Hauscihld 
A, 2006; Glaser KB, 2007).
1.11 HDACi mechanism of action
Activation of differentiation programmes, inhibition of the cell cycle 
and induction of apoptosis are the key antitumor activities of 
HDACis. These biological effects are due to HDACi-dependent 
alteration in the acetylation level of histones, transcription factors
and other proteins. In fact, the inhibition of HDACs causes the 
release of these enzymes from transcription factor complexes and 
the recruitment of HATs which acetylate histones favoring 
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decondensation of chromatin structure and activation of transcription
of tumor-suppressor genes or other genes crucial for the normal
functioning of cells (Marks PA, 2001). Although histone 
deacetylation has a fundamental role in regulating gene expression, 
HDAC inhibitors seem to directly affect transcription of only a 
relatively small number of genes (2-10%). Different HDAC inhibitors 
activate a common set of genes indicating that certain loci are more 
susceptible to these compounds than others , in particular those that 
control cell growth and survival (Johnstone RW, 2002). Moreover, 
HDAC substrates include also non-histone proteins such as 
transcription factors (e.g. p53, E2F), signal transduction mediator 
(e.g. STAT3), DNA repair enzyme (e.g. Ku70), chaperone proteins 
(e.g. Hsp90), structural proteins (α-Tubulin), steroid receptors (ERα).
HDACis induce an increase in acetylation level of these proteins 
affecting their function, stability or protein-protein interaction (Xu 
WS, 2007; Spange S, 2009). In fact, p53 acetylation increases its 
stability and binding to DNA leading to transcriptional activation of 
different p53 target genes including pro-apoptotic genes (e.g. Bax)
(Minucci S, 2006). Moreover, acetylation in the DNA-binding 
domains of Ku70 reduces its ability to repair drug-induced DNA 
damage, thereby sensitizing cancer cells to agents producing DNA 
double-strand break as radiations. This effect may account for the 
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increase of tumor cell sensitivity to chemotherapy and radiotherapy 
following HDACi treatment (Minucci S, 2006).
One of the main effects of HDACis is inhibition of the cell cycle 
which is a necessary event in cellular differentiation. Almost all 
HDACis activate transcription of the cyclin-dependent kinase (CDK) 
inhibitor p21/WAF1 encoded by the CDKN1A gene inducing 
acetylation of histones at the level of this locus (Nebbioso A, 2005).
However, the induction of p15/INK4b (CDKN2B), p16/INK4a
(CDKN2A) and p27/Kip1(CDKN1B) CDK inhibitors at transcriptional  
level has also been reported (Hitomi T, 2003; Marks PA, 2001
Nimmanapalli R, 2003). The increase in the level of p21/WAF1 or 
other CDK inhibitors causes hypophosphorylation of retinoblastoma 
tumor-suppressor protein RB and arrest of cell cycle in G1 phase 
(Johnstone RW, 2002). Analysis of the cell-cycle profiles of tumor 
cells treated with HDAC inhibitors indicates that the cells often arrest 
in G1, but sometimes accumulate in G2 phase of cell cycle (Qiu L,
2000). In fact, it has been demonstrated that SAHA at low 
concentration predominantly induces G1 arrest, while high 
concentration induces both G1 and G2/M arrests in bladder 
carcinoma cell lines (Richon VM, 2000). Furthermore, SAHA has 
been also reported to inhibit the growth of pancreatic cancer cells  
and  non-small cell lung cancer cells (NSCLC)  in a dose-dependent 
manner inducing G2/M cell cycle arrest, apoptosis and differentiation 
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(Pan LN, 2007). Most tumor cells that do not arrest in G1, after 
HDACi treatment, replicate their DNA and subsequently arrest in G2 
checkpoint (Ruefli AA, 2001; Qiu L, 2000; Glick RD,1999; Johnstone 
RW, 2002). However, many tumor cell lines accumulating replicated 
DNA and hyperacetylated histones undergo apoptosis  (Johnstone 
RW, 2002; Bao Q, 2007). In this context, HDACis can induce cell-
death of tumor cells activating both mitochondrial (intrinsic) and 
death-receptor (extrinsic) pathways of apoptosis (Figure 11). The 
pathway activated depends on the cell type and class of HDAC 
inhibitor used.  The intrinsic apoptosis pathway is usually triggered 
in response to stress conditions such as cytotoxic drugs, UV 
irradiation or growth factor withdrawal and requires disruption of the
mitochondrial membrane by Bcl-2 family pro-apoptotic members Bax 
and Bak. Following a death stimulus, the cytosolic monomeric Bax 
translocates to the mitochondria where it becomes an integral 
membrane protein and oligomerizes giving rise to voltage-
dependent anion channels which lead to mitochondrial outer 
membrane permeabilization (Johnstone RW, Ruefli AA, 2002; Bao 
Q, 2007). This event favors the release from the mitochondria of 
cytochrome c and other pro-apoptotic factors, such as 
Smac/DIABLO (Second Mitochondria-derived Activator of 
Caspases). Cytochrome c binds and activates Apaf-1 which in turn 
activates caspase-9 starting caspase cascade (Johnstone RW,
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Ruefli AA, 2002). Smac/DIABLO binds and antagonizes caspase 
inhibitors IAPs (inhibitors of apoptosis). Caspases are cysteine 
aspartate proteases expressed as inactive zymogens (pro-caspase)
and proteolitically processed to an active state after an apoptotic 
stimulus. Initiator caspases (e.g. caspase-2, -8, -9 and -10) cleave 
inactive pro-forms of effector caspases, thereby activating them. 
Effector caspases (e.g. caspase-3, -6 and -7), in turn, cleave other 
protein substrates within the cell, to trigger the apoptotic process
(Bao Q, 2007).
Bcl-2 family also includes pro-apoptotic Bad and Bim, and 
antiapoptotic Bcl2 and BclxL proteins. Bad and Bim stimulate 
activation of intrinsic pathway preventing the antiapoptotic function 
of Bcl2 and BclxL. HDACis can alter the balance of  expression of 
pro- and anti-apoptotic genes to favor a pro-apoptotic response. 
Indeed, SAHA causes upregulation of proapoptotic (Bax and Bim) 
and downregulation of antiapoptotic (IAP, Bcl-2, Bcl-xL) genes. 
Different HDACis induce also the cleavage of the pro-apoptotic 
protein Bid resulting in a C-terminal fragment (tBid) which 
translocates to mitochondria and induces the oligomerization of Bax 
and Bak opening the mitochondrial voltage-dependent anion 
channel (Korsmeyer SJ, 2000 ; Johnstone RW, 2003). 
The extrinsic pathway of apoptosis is mediated by  death receptors
including Fas (Apo-1 or CD95), tumor necrosis factor (TNF) 
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receptor-1 (TNFR-1), TNF-related apoptosis-inducing ligand (TRAIL 
or Apo2-L) receptors (DR-4 and DR-5). All death receptors are 
characterized by a cysteine-rich extracellular domain and an 
intracellular cytoplasmic sequence motif known as the death domain 
(DD). The binding of Fas-Ligand (Fas-L), TNFα and TRAIL ligands 
induce trimerization of their receptors and clustering of the receptor 
DD leading to the recruitment of the adaptor proteins FADD (FAS-
Associated Death Domain-containing protein or MORT1) which 
interacts with the death domain of the receptors through its own 
death domain. FADD also contains a death effector domain (DED) 
near its amino terminus, which facilitates binding to the DED of pro-
caspase-8 and its activation. This complex (receptor-FADD-pro-
caspase-8) of interacting proteins is referred to as the death-
inducing signalling complex (DISC) (Johnstone RW, Ruefli AA,
2002; Bao Q, 2007). Pro-caspase-8 is activated by autoproteolytic
processing and the resulting active caspase-8 cleaves and activates 
downstream effector caspases such as caspase-3, -6, and -7.
Caspase-8 can also proteolitically activate Bid which can start the 
mitochondrial pathway amplifying the apoptotic signaling. HDACis
can upregulate the expression of both death receptor and their 
ligands in transformed cells but not in normal cells (Nakata S 2004;
Insinga A 2005; Xu WS, 2007). Indeed, it has been reported that 
Fas and FasL are induced in human neuroblastoma cells by 
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hydroxamates, in nude mice xenograft of human osteosarcoma cells 
by FK228 and mouse model of acute promyelocytic leukaemia by 
valproic acid (Glick RD, 1999; Insinga A, 2005).
TRAIL is induced at mRNA level in acute myeloid leukaemia cells by 
SAHA and MS-275 and both TRAIL and DR5 are induced in the 
mouse model of APL by valproic acid (Nebbioso A, 2005; Insinga A, 
2005). TNFα is upregulated by FK228 in human promyelocytic 
leukemia cells (Xu WS, 2007). Therefore, extrinsic apoptotic 
pathway can account for HDACi-induced cell death in many 
transformed cells.
Figure 11. Schematic representation of extrinsic and intrinsic apoptotic 
pathways
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1.12 TNF-related apoptosis-inducing ligand (TRAIL)
TRAIL is one of the main mediators of HDACi-induced apoptosis
and as well as a promising candidate for cancer therapeutics due to 
its ability to induce apoptosis selectively in cancer cells in vitro and 
in vivo with little or no effect on normal cells. TRAIL was identified on 
the basis of its sequence homology to the other members of the 
TNF superfamily and is expressed as a transmembrane protein of 
33 kDa with an extracellular carboxy-terminal and intracellular 
amino-terminal portion (Ashkenazi A, 2002; MacFarlane M, 2003;
Zauli G, 2006; Kawakubo T, 2007). Cell-surface TRAIL protein can 
be processed by cysteine proteases to release the extracellular 
carboxy-terminal region (soluble TRAIL) which also leads to a higher 
induction of apoptosis in tumor cells (Zauli G, 2006; Kawakubo T).
TRAIL mRNA is expressed constitutively in a wide range of tissues 
most predominantly in spleen, lung, and prostate (MacFarlane M, 
2003). All cells of  the immune system (T-lymphocytes, B-
lymphocytes, natural killer cells, dendritic cells, monocytes and 
granulocytes) can upregulate surface TRAIL expression and/or 
release soluble TRAIL upon receiving activation signals to mediate 
anti-tumoral response or maintain the homeostasis of the lymphoid 
compartment (Zauli G, 2006). Among the TNF superfamily 
members, TRAIL is the most complex apoptotic ligand as can bind 
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five different receptors: two death receptors, DR4 and DR5 (also 
known as TRAIL-R1 and TRAIL-R2), and two decoy receptors,
DcR1 and DcR2 (also known as TRAIL-R3 and TRAIL-R4); OPG 
(osteoprotegerin) is a secreted circulating receptor that also works 
as a decoy receptor (Ashkenazi A, 2002; MacFarlane M, 2003; Zauli 
G, 2006). DR4 and DR5 are transmembrane proteins containing a 
cytoplasmic death domain to elicit an apoptotic response upon 
binding of TRAIL through DISC complex formation. DcR1 lacks the 
cytoplasmic portion  containing the death domain and is anchored to 
the cell membrane by a covalently linked C-terminal glycolipid
(glycosylphosphatidylinositol). DcR2 is a transmembrane protein 
with a truncated death domain in its cytoplasmic tail (MacFarlane M, 
2003; Zauli G, 2006). Both DcR1 and DcR2 are unable to efficiently 
transduce intracellular apoptotic signals and may compete with DR4 
and DR5 for ligand TRAIL thus working as decoy receptors. TRAIL 
receptors are expressed in most human tissues including spleen, 
thymus, peripheral blood lymphocytes and gastrointestinal tract (Pan 
G, 1997; Schneider P, 1997; Ashkenazi A, 2002; Mahalingam D, 
2008). OPG acts in a paracrine and autocrine manner by binding 
TRAIL, preventing its access to DR4 and DR5 promoting cell 
survival (Zauli G, 2006). In addition to triggering a pro-apoptotic 
signal through activation of caspases, the binding of TRAIL to death 
receptors DR4 and DR5, can activate an alternative signal 
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transduction pathway which promotes proliferation and survival 
through NF-B (nuclear factor B) transcription factor (Johnstone 
RW, 2008). Indeed, following ligand binding, TRAIL death receptors
can recruit FADD directly or TRADD (TNFR-associated death 
domain) adaptor which in turn recruits FADD to start the apoptotic 
cascade. However, TRADD can also recruit TRAF2 (TNF receptor-
associated factor 2) and RIP (receptor interacting protein) which
succesively recruit IKK ( kinase complex) favoring 
phosphorylation of NF-B inhibitor) and signaling it for 
ubiquitination and degradation (Chaudhary PM, 1997). These events 
allow NF-B to enter the nucleus and activate transcription of pro-
survival genes such as cytokines or growth factors (MacFarlane M,
2003). TRAIL seems to activate NF-B only when the apoptotic 
signalling is blocked by use of caspase inhibitor or via endogenous 
resistance mechanisms also due to defective death receptor 
signaling found in certain tumor cells (Ehrhardt H, 2003; Baader E,
2005; Johnstone RW, 2008).
Recombinant soluble TRAIL induces apoptosis in a broad spectrum 
of human cancer cell lines, including colon, lung, breast, prostate, 
pancreas, kidney, central nervous system, and thyroid cancer, as 
well as multiple myeloma, melanoma and osteosarcoma indicating 
that this ligand might be useful for the treatment of many cancers 
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(Ashkenazi A, 2002; Zauli G 2006; Wu GS, 2009; Macher-
Goeppinger S, 2009). Furthermore, unike TNF and Fas-L which 
are toxic upon systemic administration in athymic mice, injection of 
recombinant TRAIL exerts marked antitumor activity without toxicity
in both mice and non-human primates (Ashkenazi A, 2002; 
Johnstone RW, 2008). HDACIs strongly sensitized exogenous 
soluble recombinant human TRAIL-induced apoptosis synergistically 
in different tumor cell lines that were resistant to TRAIL alone
(Bolden JE, 2006; Earel JK, 2006; Newsom-Davis T, 2009).
Therefore, the recombinant form of TRAIL has recently entered a 
Phase I clinical trial as monotherapy or in combination with chemo, 
HDAC inhibitors or other anticancer drugs (Johnstone RW, 2008).
Figure 12. Apoptotic pathways activated by TRAIL ligand.
                                                                           
44
Aim of the project
The aim of our work has been to evaluate the possibility of an 
innovative therapy for anaplastic thyroid carcinoma based on 
HDACis, investigating the effects and mechanisms of action of some 
HDACis on a model of rat thyroid cells transformed by the v-ras-Ki 
oncogene, which is one of the most common genetic lesions found 
in human tumors. We have chosen SAHA (suberoylanilide 
hydroxamic acid), and MS-275 (Mitsui), two potent HDACis in 
clinical trial for the treatment of different types of tumors
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2 MATERIALS AND METHODS
2.1 Immunohistochemistry  
Immunohistochemical analysis for HDAC1, HDAC2, HDAC3 
proteins was performed by Dr. Gennaro Chiappetta (National 
Cancer Institute G. Pascale, Naples). Paraffin sections (5 to 6 µm) 
were deparaffinized, placed in a solution of absolute methanol and 
0.3% hydrogen peroxide for 30 minutes and then washed in PBS 
before immunoperoxidase staining. For HDAC1, HDAC2 and
HDAC3 slides were incubated overnight at 4°C in a humidified 
chamber with HDAC 1 rabbit polyclonal antibody (Cell Signaling 
Technology) 1:50; HDAC 2 polyclonal antibody (Santa Cruz 
Biotechnology) 1:50; HDAC 3 rabbit polyclonal antibody (Cell 
Signaling Technology) 1:50 dilution. The slides were subsequently 
incubated with biotinylated goat antirabbit/antimouse IgG for 20 
minutes (DakoLSAB2 System) and then with streptavidin 
horseradish peroxidase for 20 minutes. For immunostaining, the 
slides were incubated in 3,3’-diaminobenzidine (Dako) solution 
containing 0.06 mmol/L 3,3’-diaminobenzidine and 2 mmol/L 
hydrogen peroxide in 0.05% PBS (pH 7.6) for 5 minutes. After 
chromogen development, the slides were washed, dehydrated with 
alcohol and xylene, and mounted with coverslips with Permount 
mounting medium (Proscitech, Kirwan, Australia). The informed 
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consent for the scientific use of biological material was obtained 
from all patients.
2.2 Cell lines
FRTL-5 Cl2 and PC Cl3 are thyroid epithelial cell lines derived from 
3-week- and 18-month-old Fisher rats, respectively. These cell lines 
are not tumorigenic and retain the typical markers of thyroid 
differentiation (thyroglobulin synthesis and secretion, iodide uptake 
and dependance on TSH) (Fusco A ,1985; Fusco A, 1987). FRTL-5 
v-ras-Ki, PC Cl3 v-ras-Ki, are rat thyroid cell lines obtained from 
FRTL-5 Cl2 and PC Cl3 infected with Kirsten murine sarcoma virus 
(KiMSV) carrying ki-ras oncogene. FRTL-5 v-ras-Ki cells have lost 
the typical markers of thyroid differentiation and are completely 
transformed because they grow with high efficiency in agar and 
induce tumors after brief latency period (7-10 days) after injection in 
athymic mice. PC Cl3 v-ras-Ki lost the typical markers of thyroid 
differentiation (thyroglobulin synthesis and secretion, iodide uptake 
and dependance on TSH) but do not became fully malignantly 
transformed. PC Cl3 v-mos are rat thyroid cell lines derived from PC 
Cl3 infected with myeloproliferative sarcoma virus (MPSV) carrying 
mos oncogene and are not differentiated and they are fully 
transformed (Fusco A ,1985; Fusco A, 1987). All rat thyroid cell lines 
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were cultured in Coon’s modified Ham’s F12 medium supplemented 
with 5% calf serum, 1% penicillin/streptomycin (Gibco Laboratories, 
USA). Normal FRTL-5 Cl2 and PC Cl3 cells required 6 growth 
factors (1x10-10 M TSH, 10 µg/ml insulin, 10 nM hydrocortisone, 5 
µg/ml human transferring, 10ng/ml somatostatin, 10ng/ml glycyl-L-
histidyl-L-lysine acetate). FRO (Fagin JA, 1993) and FB1 (Fiore L, 
1997) are  human thyroid anaplastic carcinoma cell lines. They were 
grown in DMEM (Gibco Laboratories) containing 10% FCS (Gibco 
Laboratories), 1% L-glutamine (Gibco Laboratories) and  1% 
penicillin/streptomycin (Gibco Laboratories). All cell lines were 
grown at 37°C in a 5% CO2 atmosphere.
2.3 Chemicals
MS-275 (kind gift from Bayer-Schering) and MG132 (Calbiochem) 
were dissolved in ethanol while SAHA (Alexis) and MC1568 in 
dimethylsulfoxide (DMSO).
2.4 RNA and protein extraction
FRTL-5 Cl2 and FRTL-5 v-ras-Ki cells were plated in 10 cm dishes 
and treated with 5 µM SAHA and 5 µM MS-275 for 24, 48 and 72 
hours. RNA and protein were extracted as described below.
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2.4.1 RNA extraction 
RNA was extracted with TRIzol (Invitrogen). Cells were 
homogenized in 1 mL TRIzol solution and 200 µL of chloroform were 
added. The resulting mixture was vortexed for 15 seconds, 
incubated at room temperature for 15 minutes and centrifugated at 
11000 rpm for 15 minutes at 4°C. RNA contained into the aqueous 
phase was precipitated with 500 µL of isopropanol for 10 minutes at 
room temperature. The precipitate was centrifugated at 11000 rpm 
for 8 minutes at 4°C and the pellet obtained was washed with 1mL 
of 75% ethanol and centrifugated at 8000 rpm for 5 minutes at 4°C. 
After removal of supernatant the pellet was air-dried at room 
temperature and dissolved in RNase-free water (DEPC-treated
water, Ambion). RNA concentration was measured using a 
Nanodrop spectrophotometer (Thermo Scientific, USA).
2.4.2 Protein extraction
FRTL-5 Cl2 and FRTL-5 v-ras-Ki cells were treated with 5 µM SAHA 
and 5 µM MS-275, harvested and whole cell protein extracts were 
prepared as further described. Cells were washed once in cold 
Phosphate Buffered Saline (PBS) and lysed in a lysis buffer
containing 50mM Tris-HCl pH 7.4, 150mM NaCl, 1% NP40, 0.25% 
sodium deoxycholate, 1mM EDTA, 1mM phenylmethyl-sulphonyl-
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fluoride and protease inhibitor cocktail. The lysates were 
centrifugated at 14000 r.p.m. x 30 min at 4°C. Protein 
concentrations were estimated by Bradford assay (Bio-Rad, Italy).
2.5 Reverse transcription (RT) and Polymerase Chain 
Reaction (PCR)
RNA was reverse transcribed in cDNA using Qiagen QuantiTect 
Reverse Transcription kit (Qiagen, Germany). Polymerase Chain 
Reaction was performed to amplify TRAIL and β-actin or GAPDH
normalizators cDNAs using HotMaster Taq DNA Polymerase 
(Eppendorf, Germany). The thermal protocol used for TRAIL 
amplification was as follows: initial denaturation at 94°C for 2 min 
followed by 35 cycles of amplification using a thermal cycle program 
consisting of 94°C for 20 s of denaturation, 57°C for 45 s annealing, 
65°C for 45 s of extension and 65°C for 2 min of final extension.  
The primers used were as follows:
Name Sequence Amplicon 
length (bp)
Rat TRAIL forward  5’-GCTTCAGTCAGCACTTCACG-3’
Rat TRAIL reverse 5’-GTCCCAAAAATCCCCATCTT-3’ 179
Rat G6PDH forward 5’-ACAGAGTGAGCCCTTCTTCAA-3’
Rat G6PDH reverse  5’-GGAGGCTGCATCATCGTACT-3’ 106
Rat β-actin forward  5’-TCGTGCGTGACATTAAGGAG-3’
Rat β-actin reverse  5’-GTCAGGCAGCTCGTAGCTCT-3’ 110
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2.6 Western blot analysis
Protein were denaturated boiling samples in Laemmli buffer (0.25 M 
Tris-HCl pH 6.8, 8% SDS, 40% glycerol, 5% 2-mercaptoethanol, 
bromophenol blue 0.05%) for 5 min before electrophoresis. Proteins 
were subjected to SDS–PAGE (12-15% polyacrylamide) in Tris-
glycine-SDS (25 mM Tris, 192 mM glycine, 0.1% SDS) (Bio-Rad, 
Italy). After electrophoresis, proteins were transferred to 
nitrocellulose membranes (Schleicher e Schuell, Germany) in a 
buffer containing Tris-glycine (25 mM Tris, 192 mM glycine) (Bio-
Rad, Italy) and 20% methanol. The complete transfer was assessed 
using Ponceau red (Sigma Aldrich, USA) staining. After blocking 
with 5% non-fat dry milk in TBS 1x/Tween 0.1% (10 mM Tris-HCl pH 
8.0, 150 mM NaCl, 0.1% Tween-20), the membrane was incubated 
with the primary antibody overnight at 4°C. After washing with TBS 
1x/Tween 0.1%, membranes were incubated with the horseradish 
peroxidase-conjugated secondary antibody (1:3000) for 60 min at 
room temperature and the reaction was detected with 
chemioluminescence detection system (Amersham Biosciences, 
UK). The antibodies used were as follows: Acetylated-H3 (Ac-H3)
(Upstate Biotechnology, USA); p27/Kip1 (BD Transduction 
laboratories, USA); Bcl-2 (Stressgen, USA); p21/Waf-1, Bax, 
HDAC2 and GAPDH (Santa Cruz Biotechnology, USA); HDAC1, 
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HDAC3 and ERK1/2 (Cell signaling, USA); BclxL (R&D, USA), 
TRAIL  (Chemicon, USA); -Tubulin (Sigma Aldrich, USA).

2.7 RNase protection assay
The Ribonuclease (RNase) Protection Assay was performed by 
Professor Lucia Altucci research group (Seconda Università degli 
Studi di Napoli, Naples) according to standard procedures 
(Pharmingen, San Diego, California) (Altucci L, 2001; Scognamiglio, 
A, 2008). RNA of rat thyroid cell lines used for this analysis was
extracted as described above. For hybridization 6 µg of total RNA 
and 6-8 x105 cpm/µl of labeling probe were used. These fragments 
were recovered by ethanol precipitation and analyzed by 
electrophoresis on a sequencing gel (5% of urea-polyacrylamide-
bis-acrylamide). After the drying process, the gel was placed in 
contact with an autoradiographic film (Hyperfilm-MP, Amersham). 
The exposure time was overnight. The presence of the target mRNA 
in the samples was revealed by the appearance of an appropriately 
sized fragment of the probe.
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2.8 Detection of apoptosis and cell cycle analysis
FRTL-5 Cl2, FRTL-5 v-ras-Ki, PC Cl3, PC Cl3 v-ras-Ki and PC Cl3 
v-mos cell lines were treated with 5 µM SAHA and 5 µM MS-275 for 
24, 48 and 72 hours. FRTL-5 Cl2 and FRTL-5 v-ras-Ki, were also 
treated with 5 µM MC1568 for  24, 48 and 72 hours. Apoptosis was 
quantified by propidium iodide-Annexin V double staining (Altucci L, 
2001). For recycling experiments: after treatment of FRTL-5 Cl2 and 
FRTL-5 v-ras-Ki cells with SAHA and MS-275, the medium was 
replaced with fresh medium and cells remained in culture for 
additional 24 and 48 hours. Then, cells were collected and cell cycle 
was analyzed by FACS (fluorescence-activated cell sorting).
FACS analysis: 2.5 x 105 cells were collected and resuspended in
500 µL of hypotonic buffer (0.1% Triton X-100, 0.1% sodium citrate, 
50 µg/mL propidium iodide, RNase A). Cells were incubated in the 
dark for 30 min. Samples were acquired on a FACS-Calibur flow 
cytometer using the Cell Quest software (Becton Dickinson) and 
analyzed by standard procedures using the same software and the 
ModFit LT version 3 Software (Verity) (Nebbioso A, 2005; 
Scognamiglio A, 2008). Acquisition and analysis of FACS data was 
performed by Professor Lucia Altucci (Seconda Università degli 
Studi di Napoli, Naples).
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2.9 Caspase assay
FRTL-5 Cl2 and FRTL-5 v-ras-Ki were treated with 5 µM SAHA and 
5 µM MS-275 for 24 hours and then collected. Cell pellet was 
resuspended in 300 µL of a solution containing a caspase substrate
(B-Bridge)  diluted in PBS 1X. Then, the samples were incubated at 
37°C for 1h. After the reaction was concluded cell samples were 
washed, resuspended in 500 µL of Wash buffer (B-Bridge) and 
caspase-3, -8 and -9 activities were measured by FACS  (Bontempo 
P, 2007). Caspase substrates (B-Bridge, Kit) used consist of: a 
different peptide sequence which is a specific target for each 
casapase bound to a fluorochrome and to fluoromethyl ketone, a 
potent inhibitor of caspase activity. These substrates enter each cell 
and irreversibly bind to a reactive cysteine residue that resides on 
the large subunit of the active caspase, thereby inhibiting further 
enzymatic activity. The fluorescent signal is a direct measure of the 
number of active caspase enzymes present in the cell.
2.10 RNA interference
siRNAs for rat TRAIL and for negative control (All stars negative 
siRNA) were purchased from Qiagen. The sense and antisense 
strands of TRAIL siRNA were: 5’-PCAACGAGGUGAAACAGCUAdT
dT-3’(sense),5’-PUAGCUGUUUCACCUCGUUGdTdT3’(anti-sense);
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P represents 5’ phosphate. The sense strand of both TRAIL siRNA 
and the negative control siRNA were labeled with Alexa Fluor 488 at 
3’end. FRTL-5 Cl2 and FRTL-5 v-ras-Ki cells were transfected with 
siRNAs (15 nM) using Hiperfect transfection reagent (Qiagen, 
Germany) and treated with 5 µM SAHA for 24 hours. After 
treatment, the cells were collected and analyzed by FACS to 
measure both efficiency of transfection and caspase-3 activity within 
the transfected cells. The efficiency of TRAIL knock-down was 
evaluated by RT-PCR and analysis of cell-surface TRAIL protein 
levels by using an anti-TRAIL-PE (E-bioscience) antibody FACS and 
Cell Quest analyses.
2.11 Drug combination studies
FRTL-5 Cl2 and FRTL-5 v-ras-Ki were treated with 1 µM MG132 for 
3 hours and then with 1 µM or 2.5 µM SAHA for 24 hours. SAHA 
and MG132 were also combined at two different concentrations: 2.5 
µM SAHA plus 1 µM MG132 or 1 µM SAHA plus 1 µM MG132. FRO 
and FB1 cells were treated with 0.25 µM or 2 µM MG132, 
respectively, for 3 hours and then with 5 µM SAHA for 24 hours. 
After treatment, cells were collected and analyzed by FACS.
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2.12 Protein stability  
To study the half-life of TRAIL protein, FRTL-5 Cl2 and FRTL-5 v-
ras-Ki were treated with 5 µM SAHA for 24 hours and 5 µg/ml 
cycloheximide (translation inhibitor) for 2, 4 and 8 hours. After 
treatment, cells were harvested and protein extracts were analyzed
by Western blot.
2.13 Degradation assay
FRTL-5 v-ras-Ki were co-transfected with GFP (pEGFP-N1) 
(Clontech) and histidine-tagged ubiquitin (p-Ubi-His) plasmids or 
with TRAIL-GFP fusion protein (pEGFP-TRAIL) (Addgene) and 
histidine-tagged ubiquitin (p-Ubi-His) plasmids using Fugene HD
reagent (Roche). After transfection, cells were treated with 5 µM 
SAHA for 16 hours, collected and analyzed by FACS.
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3 RESULTS
3.1 HDAC expression in human thyroid tumor 
biopsies and in rat thyroid cell lines
First, we evaluated the HDAC 1, 2 and 3 protein levels in 
normal thyroid, in papillary (PTC), follicular (FTC) and 
anaplastic (ATC) thyroid carcinomas by immunohistochemistry. 
HDAC 1 and 2 proteins were found highly overexpressed in 
ATC samples when compared to normal thyroid tissue. The 
immunohistochemical results are summarized in Figure 13, A-
H. An intense nuclear staining for HDAC1 and HDAC2 was 
observed in the ATCs (Figure 13, B-H), with respect to normal 
thyroid (Figure 13, A and E); conversely, HDAC3 staining did 
not show significant differences in ATCs compared to papillary 
and follicular carcinomas as well as to normal thyroid tissue 
(not shown). Thus the increase in HDAC 1 and 2 expression 
positively correlates with malignancy (Table 2).
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*Positive cases with more than 50% of neoplastic cells showing HDAC staining
Table 2. Papillary and Anaplastic thyroid carcinoma positive cases to HDAC1 and 2 
staining by immunohistochemistry
Subsequently, we analyzed class I HDAC expression in normal 
and transformed rat thyroid cell lines. The characteristics of the 
cell lines used are summarized in Figure 14A. HDAC1 protein 
levels were higher in transformed cells (FRTL-5 v-ras-Ki and
PC E1A+v-raf) than in normal cells (FRTL-5 Cl2 and PC Cl 3). 
HDAC2 protein was more abundant in FRTL-5 v-ras-Ki than in 
FRTL-5 Cl2. No significant differences in HDAC3 expression 
levels between normal and transformed cells were observed 
(Figure 14B). The expression of the specific HDAC 1, 2, and 3 
mRNA, analyzed by RNase protection assay, essentially 
supported the data on protein levels indicating that the 
expression of class I HDACs is regulated at transcriptional level 
and that HDAC 1 and 2 are overexpressed in malignant thyroid 
cells (Figure 14C).
Histotype Cases Positive cases*
        HDAC1               HDAC2       
Papillary carcinomas 17           47%          41%
  Anaplastic carcinomas 11           55%                                 63%
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3.2 SAHA and MS-275 induce growth arrest and 
apoptosis in v-ras-Ki transformed rat thyroid cells.
To test whether the overexpression of HDAC 1 and 2 corresponds to 
the increased effect of HDACis in tumor thyroid cells, we treated 
normal (FRTL-5 Cl2 and PC Cl 3) and transformed (FRTL-5 v-ras-
Ki, PC Cl 3 v-ras-Ki, PC Cl 3 v-mos) rat thyroid cell lines with 5 µM 
SAHA or 5 µM MS-275 for 24, 48 and 72 hours. Then, we analysed  
cell cycle and apoptosis by FACS.
3.2.1 Analysis of HDACi-induced apoptotic effect 
FACS analysis in Figure 15 shows that both SAHA and MS-275 
induced apoptosis preferentially in the transformed cell lines. In fact, 
the apoptotic effect was more evident in the highly tumorigenic cell 
lines such as FRTL-5 v-ras-Ki and PC Cl 3 v-mos (Figure 15B) than 
in PC Cl 3 v-ras-Ki which did not show a malignant phenotype 
(Figure 15C), thus suggesting that HDACis might be more efficient 
in highly malignant thyroid tumors. Normal cell lines FRTL-5 Cl2 and 
PC Cl3 (Figure 15A), did not show any apoptotic effect after 
treatment. In full agreement with these findings, caspase-3 (effector 
caspase) and caspase-8, -9 (initiator caspases) were activated in 
FRTL-5 v-ras-Ki but not in FRTL-5 Cl2 (Figure 15D), thus indicating 
that caspase-dependent apoptosis mediates cell death in 
transformed cells but not in normal thyroid cells.
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3.2.2 Analysis of HDACi-induced cell cycle arrest
In a similar experimental setting, the cell cycle analysis did not show 
significant differences between tumor and normal cell lines (Figure 
16, A and B). Moreover, both SAHA and MS-275 vehicles (DMSO 
and ethanol respectively) did not affect cell cycle or apoptosis of the 
analyzed cell lines at the concentration used. Furthermore, the 
evaluation of histone H3 acetylation by Western blot analysis (Figure
16C) did not display significant differences of acetylated histone 
regulation among FRTL-5 Cl2 and their tumoral ras version. Indeed, 
we could detect an increase of H3 acetylation and a cell cycle arrest 
in both normal and cancer cells.
However, to evaluate the extent of SAHA and MS-275 effects in
these thyroid cell lines, we treated FRTL-5 Cl2 and FRTL-5 v-ras-Ki 
cell lines as previously described, removing the drugs and allowing 
the cells to grow for additional 24 and 48 hours. As shown in Figure
16D, FRTL-5 Cl2 re-entered the S phase after drug removal, while  
FRTL-5 v-ras-Ki treated for 72 hours, but not those treated for 24 
and 48 hours (not shown), remained blocked in G1 phase going 
towards death. These results, corroborate the low toxicity of SAHA 
and MS-275 for normal thyroid cells, thus stressing the selectively 
induced cell death caused by HDAC inhibitors in transformed cells. 
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3.2.3 Inhibition of Class I HDACs is crucial for
HDACi-Induced apoptosis and cell cycle arrest
Finally, the compound MC1568, which is known to inhibit only 
class II HDACs (Mai A, 2005; Duong V, 2008) (SAHA and MS-
275 inhibit also or only class I HDACs), induced only a slight 
G1 arrest, but did not cause apoptosis in both FRTL-5 Cl2 and 
FRTL-5 v-ras-Ki (Figure 17). This evidence suggests that the 
apoptotic effects induced by SAHA and MS-275 in the FRTL-5 
v-ras-Ki cells are due to the inhibition of class I HDACs and, in 
particular, to the block of HDAC 1 and 2, the only HDACs 
mainly inhibited by MS-275 (Nebbioso A, 2005) and found 
overexpressed in  thyroid carcinomas (Figure 13).
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3.3 SAHA and MS-275 alter regulatory protein levels in
FRTL-5 v-ras-Ki thyroid cells
In order to understand the molecular events occurring upon HDACi 
treatment and underlying to the selective tumor cell death, we 
evaluated the levels of known proteins involved in apoptosis such as 
Bax, Bcl2, BclxL, in both FRTL-5 Cl2 and FRTL-5 v-ras-Ki before 
and after treatment. The treatment with both HDACis did not affect 
the protein levels of Bax and Bcl2, whereas BclxL was up-regulated 
in normal and down-regulated in cancer cells (Figure 18). High 
levels of BclxL could be important in blocking the apoptotic process 
in normal cells. When cell cycle related proteins were investigated, 
p21/WAF1 was induced only by MS-275 in both normal and 
transformed cells, whereas p27/Kip1 was induced by both drugs 
only in normal cells. Therefore, it is reasonable to speculate that p27 
induction might be responsible for the cell cycle arrest caused by 
these HDACis in normal thyroid cells. 
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It has previously been demonstrated that TRAIL (TNFSF10, Apo2L, 
TNFSF10-Tumor necrosis factor ligand superfamily member 10) is 
induced by HDACis (Nebbioso A, 2005) and that its action displays 
some tumor selective feature (Hall MA, 2007; Johnstone RW, 2008)
although the mechanisms for this remain presently obscure. 
Therefore, we analyzed TRAIL expression by Western blot in normal 
and transformed cells. As shown in Figure 19 both SAHA and MS-
275 induced TRAIL protein only in FRTL-5 v-ras-Ki cells. Although 
TRAIL regulation at transcriptional level has previously been 
described (Nebbioso A, 2005), in our system, RT-PCR analysis did 
not show significant differences between treated and untreated, 
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normal and transformed cells in TRAIL mRNA expression level 
(Figure 19B), thus suggesting that a different regulation is occurring.  
3.4 TRAIL is the main mediator of cell death induced by 
SAHA
Intrigued by the TRAIL induction stimulated by HDACis in tumor 
thyroid cells, we transiently knocked down TRAIL by an interference 
methodology in FRTL-5 Cl2 and FRTL-5 v-ras-Ki cell lines. The 
TRAIL mRNA expression was drastically reduced in the siTRAIL 
transfected cells as the efficiency of TRAIL knock-down, evaluated 
by RT-PCR and TRAIL protein cell-surface level analysis (Figure 
19C), clearly demonstrates. Interestingly, TRAIL silencing caused a 
significant reduction (61%) in caspase-3 activation in FRTL-5 v-ras-
Ki compared to the same SAHA-treated cells transfected with a 
scramble siRNA (Figure 19D). The analysis of caspase-3 performed 
only in the transfected cells ensured that the decrease in apoptosis 
occurred for TRAIL silencing. This result indicates that TRAIL is a 
main mediator of the apoptosis induced by HDACis in transformed 
thyroid cells.
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3.5 SAHA and MS-275 induce TRAIL protein 
stabilization
Since our data indicate that SAHA and MS-275 induce TRAIL only 
at protein level, we hypothesized that HDACis stabilized TRAIL by 
altering its degradation, likely by proteasome mediation. To 
demonstrate this hypothesis, we treated both FRTL-5 Cl2 and 
FRTL-5 v-ras-Ki cells with 1 µM or 2.5 µM SAHA in presence or 
absence of 1 µM MG132, a known proteasome inhibitor. The 
combined treatment of SAHA with MG132 resulted in a significant 
increase in TRAIL protein level in transformed cells in comparison 
with the single treatments. Conversely and in agreement with our 
previous data (Figure 20A), TRAIL was not detectable in both 
treated and untreated normal cells. The evaluation of the cell cycle 
and apoptosis by FACS in normal and transformed thyroid cells in 
these experimental settings, showed an apoptosis much higher in 
FRTL-5 v-ras-Ki treated with both SAHA and MG132 than that 
observed for the cells singularly treated (24% with SAHA, 10% with 
MG132). Conversely, FRTL-5 Cl2 normal thyroid cells were arrested 
in G1 phase but did not undergo apoptosis after treatment (Figure 
20 B and C). These results strongly indicate that SAHA and MG132 
synergize in killing tumor cells through the stabilization of death 
ligand TRAIL.

                                                                           
71
In order to confirm that TRAIL is stabilized by HDACis, we analyzed 
the half-life of TRAIL in FRTL-5 Cl2 and FRTL-5 v-ras-Ki treated 
with 5 µM SAHA for 24 hours and 5 µg/ml cycloheximide for 2, 4 and 
8 hours to block mRNA translation. As shown in Figure 20D, TRAIL 
protein disappeared after 8 hours in FRTL-5 v-ras-Ki treated only 
with cycloheximide, whereas was still present after 8 hours in 
cycloheximide-SAHA treated cells indicating that SAHA treatment 
induces an increase of the TRAIL protein half-life. 
To further demonstrate that SAHA reduces TRAIL protein 
degradation affecting the ubiquitin-dependent pathway we co-
trasfected FRTL-5 v-ras-Ki cells with pEGFP-N1 and p-Ubi-His or 
with pEGFP-TRAIL and p-Ubi-His. We determined the degradation 
of TRAIL-GFP fusion protein by evaluating cell fluorescence by 
FACS after treatment with 5 µM SAHA for 16 hours. The amount of 
exogenous TRAIL, proportional to the cell fluorescence, increased 
after treatment with SAHA, whereas was reduced after 
overexpression of ubiquitin (Figure 21). Taken together, these 
results indicate that SAHA reduces TRAIL degradation in thyroid 
transformed cells by altering the ubiquitin-dependent pathway of 
degradation. 
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3.6 HDACi effects on human anaplastic thyroid
carcinoma cell lines
Finally, to demonstrate that our findings can be extended also to 
human anaplastic cells and can be useful for an alternative therapy 
of the thyroid anaplastic cancer, we verified the efficacy of the 
combination MG132+SAHA on FRO, a human anaplastic thyroid cell 
line. We treated the FRO cells (Fagin J.A.,1993) with 5 µM SAHA, 
0.25 µM MG132 or with the combination of both drugs. While the 
single treatments did not induce cell cycle arrest (Figure 22A), the 
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combination SAHA + MG132 had a synergistic effect in inducing 
apoptosis in FRO cells as previously shown for FRTL-5 v-ras-Ki 
cells (Figure 20C). Indeed, the combined treatment caused an 
evident increase in apoptosis compared to the single treatments 
(Figure 22B). Analogous results were obtained for FB1 (Figure 22D), 
another human anaplastic thyroid cell line (Fiore L, 1997), thus 
suggesting that this combination treatment might be useful against 
anaplastic thyroid cancer.
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4 DISCUSSION
The anaplastic thyroid carcinoma represents one of the most lethal 
human neoplasms, being refractory to conventional treatment as 
chemo- and radiotherapy. Recently, an  innovative tumor therapy 
based on the use of HDACis has been proposed and already 
introduced in clinical experimentation. Therefore, the elucidation of 
their mechanisms of action becomes extremely important (Glaser 
KB, 2007). 
In this study we have analyzed the effects of two potent HDAC 
inhibitors, named SAHA (Vorinostat, Zolinza) and MS-275, in a well 
defined cell system where the process of tumor transformation is 
well known allowing a better comprehension of the mechanisms 
through which these drugs may act. The cell system studied here is 
represented by the rat thyroid cells infected with the Kirsten murine 
sarcoma virus carrying the v-ras-Ki oncogene (Fusco A,1987).
These cells have lost the expression of the typical markers of thyroid 
differentiation, grow with a high efficiency in soft agar and induce 
tumors after injection into athymic mice. The critical role of ras gene 
activation in some thyroid cancer histotypes was confirmed by the 
induction of thyroid follicular carcinomas associated to lung 
metastasis following the injection of the Kirsten murine sarcoma 
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virus into the thyroid gland of adult Fischer rats (Portella G, 1989).
The importance  of ras oncogene in thyroid cancer is also evident in 
human follicular and anaplastic carcinoma in which there is a high
frequency of mutation in this gene as described above (Nikiforova, 
MN, 2003).
SAHA and MS-275 have a different spectrum of action, as SAHA 
inhibits both class I and II HDACs, whereas MS-275 inhibits only 
HDAC 1, 2, and 3 to a lower extent. They are already object of 
clinical trials for the treatment of solid and hematological tumors with 
minor side effects  (Mai A, 2008). Particularly, SAHA (Vorinostat, 
Zolinza) has been approved by the Food and Drug Administration 
for the treatment of cutaneous manifestations of T-cell lymphoma in 
cancer patients. Previous studies have shown that SAHA arrests cell 
growth, induces apoptosis of a wide variety of transformed cells and 
inhibits tumor growth in animal models bearing solid tumors and 
hematological malignancies (Marks PA, 2007). Indeed, SAHA and 
MS-275 display antitumor activity in acute myeloid leukemia 
mediated by both p21/WAF1 and the tumor-selective death ligand 
TRAIL (Nebbioso A, 2005; Insinga A, 2005; Altucci L, 2005). 
Moreover, the relevance for the mitochondrial pathway of apoptosis 
after treatment with HDAC inhibitors has been also demonstrated in 
B cell lymphoma (Lindemann, RK, 2007), thus indicating that more 
than one mechanism might underlie the HDACi anticancer action 
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and that tissue context may play a relevant role, and needs to be 
considered.
In this study, we show that both SAHA and MS-275 induce 
apoptosis in rat thyroid transformed cells with highly malignant 
phenotype, but not in normal cells. The increase in the activities of 
caspase-8 and -9, induced by the treatment with these drugs, 
suggested that both SAHA and MS-275 can activate mitochondrial 
and death receptor apoptotic pathways. Despite both BclxL and 
TRAIL were regulated differentially in normal and tumor cells, we 
obtained a decrease in HDACi-mediated apoptosis by the silencing 
TRAIL expression, thus indicating that TRAIL is a key mediator of 
HDACi-induced apoptosis in thyroid carcinoma cells. The absence 
of significant differences in TRAIL transcript levels in both normal 
and transformed cells suggested TRAIL regulation at the protein 
level. This hypothesis appears confirmed by i) the synergistic 
apoptotic effect of SAHA and the proteasome inhibitor MG132; ii) 
the  proportional increase of TRAIL protein level in the combo-
treatment with respect to the single one; iii) the clear increase in 
TRAIL half-life induced by SAHA.
Therefore, our results suggest a new molecular mechanism by 
which HDACis regulate cell death via a proteasome-dependent 
stabilization of TRAIL. Our demonstration that i) TRAIL is degraded 
through a ubiquitin-proteasome pathway and ii) SAHA stabilizes 
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TRAIL protein by reducing its proteasome degradation is a fully 
novel finding that explains, at the molecular level, why the 
combination of a proteasome and a HDAC inhibitor might be 
successful in anaplastic thyroid cancers.
In agreement with our findings, the synergism of  proteasome 
inhibitors with HDACis has recently been reported in glioma, in 
cervical cancer and in leukemia (Miller CP, 2007; Dai Y,2008; Yu,
2008; Miller CP, 2009; Lin Z, 2009) strongly supporting our 
molecular model and suggesting the application of this combined 
treatment in other types of cancers.
Thus, the synergism between MG132 and SAHA through 
TRAIL signaling pathway activation encourages the pre-clinical 
application of the combination of HDACis with proteasome inhibitors 
such as Bortezomib, or with drugs able to activate TRAIL apoptotic 
pathway. Our findings may contribute to the development of a novel, 
molecularly-based, approach in thyroid cancer treatment.
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